ClinicalTrials.gg
RecruitingNCT06544343TEMPLATEUpdated Aug 9, 2024

Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy

An interventional study of Remote Monitoring and On site monitoring in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus, sponsored by University Of Perugia. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by University Of Perugia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Arthritis, Rheumatoid with a site in Italy — 20 open to participants now, 30 under way, 3 of them phase 3. Arthritis, Rheumatoid · Italy.

Planned enrollment
96th of 146
190 · median 319
Started
2024
with 4 others
No phase
9 of 189
5 open now
Primary completion
2026-03
later than 7 of 29 live
Registered
175th of 189
by date

Among the 189 studies in Arthritis, Rheumatoid with a site in Italy, this one is the 96th largest by planned enrollment of the 146 interventional ones that give a count, is one of 5 that started in 2024, is one of 9 with no phase, reaches primary completion later than 7 of the 29 other live ones, and was the 175th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

20 of the 189 studies in Arthritis, Rheumatoid with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Arthritis, Rheumatoid with a site in Italy, or all of them as a file.
02

Study summary

Systemic autoimmune and chronic inflammatory diseases are a group of chronic illnesses whose treatment is usually very prolonged, often lifelong, and is essential to keep the disease under control, thus reducing the risk of complications and allowing the best possible quality of life for patients.

The drugs used for treating these diseases are mostly immunosuppressants, which reduce the activity of the immune system, whose alteration is responsible for the disease. Although all available drugs are effective for treating these diseases, for reasons largely unknown, each drug is effective only in a percentage of patients. As a result, it is often necessary to try several different treatments before identifying an effective one for the individual patient.

The therapeutic effects are often slow, and it is therefore necessary to take a treatment for weeks or months before its effectiveness can be determined. The initial period is also when side effects most often appear. The aim of this study is to evaluate whether the addition of remote monitoring visits and other patient support services to traditional periodic medical visits in the first months after the introduction of a new treatment leads to an improvement in adherence, response, and quality of life for the patient.

03

Conditions studied

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis
  • Spondyloarthritis, Axial
  • Ankylosing Spondylitis

Keywords

  • Immunosuppression
  • Quality of Life
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Any patient with one of the following conditions

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Spondyloarthritis
  • Ankylosing Spondylitis
  • Systemic Sclerosis
  • Systemic Lupus Erythematosus
  • Sjogren's Disease who are prescribed a new medication for the treatment of their disease among the following:
  • Methotrexate
  • Sulfasalazine
  • Leflunomide
  • Mycophenolate Mofetil
  • Azathioprine
  • Cyclosporine A
  • Tacrolimus
  • TNF inhibitors (etanercept, adalimumab, golimumab, certolizumab pegol)
  • IL6 inhibitors (tocilizumab)
  • IL-17 inhibitors (secukinumab, ixekizumab)
  • IL-23 inhibitors (ustekinumab, guselkumab, risankizumab)
  • JAK-inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib)
  • Belimumab
  • Anifrolumab

Exclusion criteria

Exclusion Criteria:

  • Treatment with a medication not approved for the condition
  • Inability to use a device for remote call, not even with the help of a caregiver
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Remote Monitoring

    Other: Remote Monitoring · Other: On site monitoring

  • Placebo comparator
    On site only

    Other: On site monitoring

Interventions

  • OtherRemote Monitoring

    Follow-up at outpatient clinic at 3 and 6 months from drug prescription Two remote consultations at 15 and 45 days from drug prescription

  • OtherOn site monitoring

    Follow-up at outpatient clinic at 3 and 6 months from drug prescription.

06

What researchers measure

Primary outcomes

  1. Treatment persistence

    Percentage of patients taking the same medication prescribed at baseline

    Time frame: 6 months

Secondary outcomes

  1. Treatment Persistence

    Percentage of patients taking the same medication prescribed at baseline

    Time frame: 3 months

  2. Disease activity score on 28 joints with C-Reactive Protein (DAS28-CRP)

    Only applies to rheumatoid arthritis patients

    Time frame: 3 months

  3. Disease activity score on 28 joints with C-Reactive Protein (DAS28-CRP)

    Only applies to rheumatoid arthritis patients

    Time frame: 6 months

  4. Psoriatic Arthritis Disease Activity Score (PASDAS)

    Only applies to psoriatic arthritis patients

    Time frame: 3 months

  5. Psoriatic Arthritis Disease Activity Score (PASDAS)

    Only applies to psoriatic arthritis patients

    Time frame: 6 months

  6. Body Surface Area (BSA)

    Percentage of skin surface with psoriatic lesions. Only applies to psoriatic arthritis patients

    Time frame: 3 months

  7. Body Surface Area (BSA)

    Percentage of skin surface with psoriatic lesions. Only applies to psoriatic arthritis patients

    Time frame: 6 months

  8. Minimal Disease Activity (MDA)

    Binary outcome. Only applies to psoriatic arthritis patients

    Time frame: 3 months

  9. Minimal Disease Activity (MDA)

    Binary outcome. Only applies to psoriatic arthritis patients

    Time frame: 6 months

  10. Modified Rodnan's skin score

    Only applies to systemic sclerosis patients

    Time frame: 3 months

  11. Modified Rodnan's skin score

    Only applies to systemic sclerosis patients

    Time frame: 6 months

  12. Medical Research Council (MRC) dyspnoea scale

    Only applies to systemic sclerosis patients with interstitial lung disease

    Time frame: 3 months

  13. Medical Research Council (MRC) dyspnoea scale

    Only applies to systemic sclerosis patients with interstitial lung disease

    Time frame: 6 months

  14. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)

    Only applies to Sjogren's disease patients

    Time frame: 3 months

  15. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)

    Only applies to Sjogren's disease patients

    Time frame: 6 months

  16. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)

    Only applies to Sjogren's disease patients

    Time frame: 3 months

  17. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)

    Only applies to Sjogren's disease patients

    Time frame: 6 months

  18. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K

    Only applies to systemic lupus erythematosus patients

    Time frame: 3 months

  19. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K

    Only applies to systemic lupus erythematosus patients

    Time frame: 6 months

  20. Ankylosing Spondylitis Disease Activity Score (ASDAS)

    Only applies to ankylosing spondylitis and axial spondyloarthritis patients

    Time frame: 3 months

  21. Ankylosing Spondylitis Disease Activity Score (ASDAS)

    Only applies to ankylosing spondylitis and axial spondyloarthritis patients

    Time frame: 6 months

  22. Health Assessment Questionnaire Disability Index (HAQ-DI)

    Range 0 (best condition) - 3 (worst condition)

    Time frame: 3 months

  23. Health Assessment Questionnaire Disability Index (HAQ-DI)

    Range 0 (best condition) - 3 (worst condition)

    Time frame: 6 months

  24. Anxiety and Depression

    Hospital Anxiety and Depression Scale - Anxiety and Depression range 0 - 21 each (higher values mean higher degrees of depression or anxiety)

    Time frame: 3 months

  25. Anxiety and Depression

    Hospital Anxiety and Depression Scale - Anxiety and Depression range 0 - 21 each (higher values mean higher degrees of depression or anxiety)

    Time frame: 6 months

  26. EQ-5D-5L score

    The score measures quality of life and includes 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which is scored from 1 (perfect health) to 5 (complete inability).

    Time frame: 3 months

  27. EQ-5D-5L score

    The score measures quality of life and includes 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which is scored from 1 (perfect health) to 5 (complete inability).

    Time frame: 6 months

  28. Number of phone calls to Rheumatology Outpatient Clinic

    Time frame: 6 months

  29. Number of additional, unscheduled rheumatology consultations

    Time frame: 6 months

  30. Number of consultations to GP due to prescribed treatment-related issues

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Rheumatology Unit - Perugia Univeristy Hospital
    Perugia, PG 06129, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Mar 2026, 20 months after the start.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 20 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2024
First posted
Aug 9, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Mar 18, 2026
CompletionEst.
Mar 18, 2026
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06544343
Lead sponsor
University Of Perugia
Responsible party
Elena Bartoloni Bocci (Associate Professor, University Of Perugia) — Principal investigator
First posted
Aug 9, 2024
Start date
Jul 1, 2024
Primary completion
Mar 18, 2026 (estimated)
Completion
Mar 18, 2026 (estimated)
Last update
Aug 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion